Abstract
Levels of iron and iron-related proteins including ferritin are higher in the lung tissue and lavage fluid of individuals with chronic obstructive pulmonary disease (COPD), when compared to healthy controls. Whether more iron in the extracellular milieu of the lung associates with distinct clinical phenotypes of COPD, including increased exacerbation susceptibility, is unknown. We measured iron and ferritin levels in the bronchoalveolar lavage fluid (BALF) of participants enrolled in the SubPopulations and InteRmediate Outcome Measures In COPD (SPIROMICS) bronchoscopy sub-study (n = 195). BALF Iron parameters were compared to systemic markers of iron availability and tested for association with FEV1 % predicted and exacerbation frequency. Exacerbations were modelled using a zero-inflated negative binomial model using age, sex, smoking, and FEV1 % predicted as clinical covariates. BALF iron and ferritin were higher in participants with COPD and in smokers without COPD when compared to non-smoker control participants but did not correlate with systemic iron markers. BALF ferritin and iron were elevated in participants who had COPD exacerbations, with a 2-fold increase in BALF ferritin and iron conveying a 24% and 2-fold increase in exacerbation risk, respectively. Similar associations were not observed with plasma ferritin. Increased airway iron levels may be representative of a distinct pathobiological phenomenon that results in more frequent COPD exacerbation events, contributing to disease progression in these individuals.
Similar content being viewed by others
Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and morbidity worldwide, resulting in almost 3 million deaths globally in 2016 and the loss of over 47 million potential life-years1. A significant portion of this burden of disease presents as exacerbation events, episodic surges of respiratory symptoms accompanied by a more rapid decline in lung function and higher mortality2,3. These exacerbations are largely attributed to recurrent acute infection, with host factors also playing a fundamental role4. Identifying and understanding host susceptibility risk factors that contribute to repeated exacerbations is imperative to understanding and treating COPD.
Although the overwhelming risk factor in the industrialized world for COPD development is tobacco smoking, genome wide association studies suggest a pathogenic role for abnormal iron homeostasis5. We recently demonstrated that a major iron metabolism protein, iron regulatory protein 2 (IRP2), drives lung inflammation and injury in a murine model of COPD5,6. In the lung, iron is found in both unbound and protein-bound forms, and several of the most abundant proteins in lung tissue and bronchoalveolar lavage fluid (BALF) bind to and regulate iron7,8,9. One such protein is ferritin, an octahedral polymeric shell composed of light chain (FTL) and heavy chain (FTH) subunits that stores ferric (Fe3+) iron atoms in a soluble, non-toxic form10. Previous studies have demonstrated release of ferritin from iron-loaded alveolar macrophages (AMs) in smokers, and AM ferritin mRNA levels are increased in active smokers and correlate with airflow limitation in COPD patients11,12. Furthermore, total levels of non-heme iron and of other iron-binding molecules including lipocalin-2 and lactoferrin, are increased in lung tissue, sputum, BALF, and AMs of COPD patients, relative to non-smokers9,11,12,13,14,15,16,17,18,19,20,21. Conversely, there is also ample evidence for iron deficiency in COPD, and anaemia in COPD is associated with worse patient outcomes, including mortality22,23. The biological relevance of such observations remains to be elucidated; however, these data strongly support a local iron overload signature in the extracellular milieu of the lung in COPD that is distinctive to systemic iron handling, which is intriguing as mainstream cigarette smoke contains little iron24,61.
Clinical data was collected at the baseline study visit and in follow-up visits as previously described27. Peripheral blood was collected as part of the baseline visit, and plasma biomarkers were measured using a Luminex-based multiplex assay; relevant to this study, plasma ferritin was shown to be equivalent to serum ferritin using this assay method62. Exacerbations were defined as health care utilization events (office visit, hospital admission, or emergency department visit for a respiratory flare-up) that were treated with antibiotics, systemic corticosteroids, or both. Exacerbation history was prospectively collected every 3 months for up to 5 years using a structured questionnaire2,60.
A subgroup of subjects (n = 215) with post-bronchodilator FEV1 > 30% predicted and without an exacerbation in the prior six weeks were further enrolled in the bronchoscopy sub-study, in which on the first of two visits, sputum induction was performed as previously described63. On the second visit, post-bronchodilator FEV1 was measured and only subjects with an FEV1 > 30% predicted were allowed to participate in the bronchoscopy portion of the study. BAL was performed in the right middle lobe and lingula by instilling two aliquots of 40 mL and one aliquot of 50 mL per lobe (260 mL total volume), after excluding an initial airway wash sample. Unfiltered BALF fluid was collected into a sterilized beaker or in multiple 50 mL conical tubes on ice, then centrifuged at 300 x g for 5 min and the supernatant aliquoted into 1 mL aliquots for storage at −80 °C, representing one BALF sample per patient as described previously63,64. Because no research plasma samples were obtained in the bronchoscopy sub-study, the plasma biomarkers, including ferritin, in this analysis were measured from the baseline visit samples. For participants in the bronchoscopy sub-study, exacerbation events were analysed both relative to the baseline visit and to the bronchoscopy visit (0-14 months after baseline visit).
To replicate the study findings in an independent cohort, never smokers (n = 20), healthy smokers (n = 21) with normal lung function and individuals with COPD (n = 18), recruited by the Department of Genetic Medicine, Weill Cornell Medical College underwent bronchoscopy with BALF isolated as described above (see Supplementary Information and Supplemental Table 1).
Ferritin measurement and normalization
BALF ferritin was quantified by ELISA using the Abcam Human Ferritin ELISA Kit (Cat#ab200018), which detects both ferritin heavy and light chain. BALF ferritin was normalized to total protein, measured using the Thermo Scientific Pierce BCA Protein Assay Kit (Cat#23225).
Total iron measurements
After centrifugation (1000 × g for 5 mins), 60 μL of BALF was digested with 40 μL of 50% Nitric Acid (in distilled H2O) containing a final concentration of 0.1% digitonin for 2 hours at 60 °C. Total iron, including both bound and unbound forms, was measured in triplicate in 20 μL of digested fractions using a graphite furnace atomic absorption spectrophotometer (GFAAS, Perkin Elmer PinAAcle 900z), comparing unknown values to a standard curve of known concentrations of iron (1000 PPM in 2% Nitric Acid).
Statistical analysis
Clinical characteristics of SPIROMICS participants enrolled in the bronchoscopy sub-study were compared to those of all SPIROMICS participants, summarized using means and standard deviations or counts and percentages as appropriate. BALF Ferritin and iron were analysed on the log 10 scale. Plasma ferritin, haemoglobin and CRP were measured as previously described62, and analysed on the log scale, accounting for site and batch effects. Associations between BALF ferritin and baseline characteristics were performed using Kruskal-Wallis tests for categorical variables, and Pearson correlations for continuous variables, and were unadjusted unless otherwise specified. Sensitivity analyses including all SPIROMICS participants were also performed to study associations in the overall cohort. COPD exacerbations were analyzed in three ways. First, participants were dichotomized into those with any exacerbations between their baseline visit and the end of study follow-up versus those without exacerbations in this timeframe, and ferritin levels were compared across groups. Second, participants were dichotomized into those with any exacerbations between the bronchoscopy visit and the end of the study follow-up, versus those without, and ferritin levels were compared across groups. Third, the rate of exacerbations per participant per year was estimated using a negative binomial zero-inflated model, with % FEV1 predicted as the predictor in the binomial model. Ferritin associations were studied in models unadjusted as well as adjusted for age, sex, and smoking status at baseline or at the time of the bronchoscopy, as appropriate. Adjustment for study site prevented model convergence and was thus removed. Yearly exacerbation rate ratios, as well as 95% confidence intervals (CI) were estimated, and the unadjusted model was then used to plot predicted exacerbation rates in three years in a participant with a median FEV1% predicted. BALF ferritin levels in a validation cohort (see Supplemental Table 1) were similarly analysed on a log 10 scale, and compared across non-smokers, smokers without COPD, and participants with COPD.
References
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1151–1210, https://doi.org/10.1016/s0140-6736(17)32152-9 (2017).
Han, M. K. et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet. Respir Med 5, 619–626, https://doi.org/10.1016/S2213-2600(17)30207-2 (2017).
Soler-Cataluna, J. J. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60, 925–931, https://doi.org/10.1136/thx.2005.040527 (2005).
Qureshi, H., Sharafkhaneh, A. & Hanania, N. A. Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. Ther Adv Chronic Dis 5, 212–227, https://doi.org/10.1177/2040622314532862 (2014).
DeMeo, D. L. et al. Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. American journal of human genetics 85, 493–502, https://doi.org/10.1016/j.ajhg.2009.09.004 (2009).
Cloonan, S. M. et al. Mitochondrial iron chelation ameliorates cigarette smoke-induced bronchitis and emphysema in mice. Nat Med 22, 163–174, https://doi.org/10.1038/nm.4021 (2016).
Heilig, E. A. et al. Manganese and iron transport across pulmonary epithelium. American journal of physiology. Lung cellular and molecular physiology 290, L1247–1259, https://doi.org/10.1152/ajplung.00450.2005 (2006).
Wu, L., Ma, L., Nicholson, L. F. & Black, P. N. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respiratory medicine 105, 329–336, https://doi.org/10.1016/j.rmed.2010.11.001 (2011).
Fracchia, A. et al. A comparative study on ferritin concentration in serum and bilateral bronchoalveolar lavage fluid of patients with peripheral lung cancer versus control subjects. Oncology 56, 181–188, doi:11962 (1999).
Meyron-Holtz, E. G., Moshe-Belizowski, S. & Cohen, L. A. A possible role for secreted ferritin in tissue iron distribution. Journal of neural transmission (Vienna, Austria: 1996) 118, 337–347, https://doi.org/10.1007/s00702-011-0582-0 (2011).
Wesselius, L. J., Nelson, M. E. & Skikne, B. S. Increased release of ferritin and iron by iron-loaded alveolar macrophages in cigarette smokers. American journal of respiratory and critical care medicine 150, 690–695 (1994).
Philippot, Q. et al. Increased iron sequestration in alveolar macrophages in chronic obstructive pulmonary disease. PloS one 9, e96285, https://doi.org/10.1371/journal.pone.0096285 (2014).
Takemoto, K., Kawai, H., Kuwahara, T., Nishina, M. & Adachi, S. Metal concentrations in human lung tissue, with special reference to age, sex, cause of death, emphysema and contamination of lung tissue. International archives of occupational and environmental health 62, 579–586 (1991).
Corhay, J. L. et al. Iron content in human alveolar macrophages. The European respiratory journal 5, 804–809 (1992).
Ghio, A. J. et al. Particulate matter in cigarette smoke alters iron homeostasis to produce a biological effect. American journal of respiratory and critical care medicine 178, 1130–1138, https://doi.org/10.1164/rccm.200802-334OC (2008).
Iwamoto, H. et al. Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap. The. European respiratory journal 43, 421–429, https://doi.org/10.1183/09031936.00024313 (2014).
Mateos, F., Brock, J. H. & Perez-Arellano, J. L. Iron metabolism in the lower respiratory tract. Thorax 53, 594–600 (1998).
Thompson, A. B., Bohling, T., Heires, A., Linder, J. & Rennard, S. I. Lower respiratory tract iron burden is increased in association with cigarette smoking. The Journal of laboratory and clinical medicine 117, 493–499 (1991).
McGowan, S. E. & Henley, S. A. Iron and ferritin contents and distribution in human alveolar macrophages. The Journal of laboratory and clinical medicine 111, 611–617 (1988).
Wesselius, L. J., Flowers, C. H. & Skikne, B. S. Alveolar macrophage content of isoferritins and transferrin. Comparison of nonsmokers and smokers with and without chronic airflow obstruction. The American review of respiratory disease 145, 311–316, https://doi.org/10.1164/ajrccm/145.2_Pt_1.311 (1992).
Nelson, M. E., O’Brien-Ladner, A. R. & Wesselius, L. J. Regional variation in iron and iron-binding proteins within the lungs of smokers. American journal of respiratory and critical care medicine 153, 1353–1358, https://doi.org/10.1164/ajrccm.153.4.8616566 (1996).
Martinez-Rivera, C. et al. Anemia is a mortality predictor in hospitalized patients for COPD exacerbation. COPD 9, 243–250, https://doi.org/10.3109/15412555.2011.647131 (2012).
Putcha, N. et al. Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS. Ann Am Thorac Soc 15, 710–717, https://doi.org/10.1513/AnnalsATS.201708-687OC (2018).
Mussalo-Rauhamaa, H., Leppanen, A., Salmela, S. S. & Pyysalo, H. Cigarettes as a source of some trace and heavy metals and pesticides in man. Archives of environmental health 41, 49–55, https://doi.org/10.1080/00039896.1986.9935765 (1986).
Behera, S. N., **an, H. & Balasubramanian, R. Human health risk associated with exposure to toxic elements in mainstream and sidestream cigarette smoke. Sci Total Environ 472, 947–956, https://doi.org/10.1016/j.scitotenv.2013.11.063 (2014).
Agoro, R., Taleb, M., Quesniaux, V. F. J. & Mura, C. Cell iron status influences macrophage polarization. PloS one 13, e0196921, https://doi.org/10.1371/journal.pone.0196921 (2018).
Couper, D. et al. Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax 69, 491–494, https://doi.org/10.1136/thoraxjnl-2013-203897 (2014).
Hallberg, L. et al. Screening for iron deficiency: an analysis based on bone-marrow examinations and serum ferritin determinations in a population sample of women. Br J Haematol 85, 787–798 (1993).
Evensen, K. J., Swaak, T. J. & Nossent, J. C. Increased ferritin response in adult Still’s disease: specificity and relationship to outcome. Scand J Rheumatol 36, 107–110, https://doi.org/10.1080/03009740600958504 (2007).
Zandman-Goddard, G. & Shoenfeld, Y. Ferritin in autoimmune diseases. Autoimmun Rev 6, 457–463, https://doi.org/10.1016/j.autrev.2007.01.016 (2007).
Kernan, K. F. & Carcillo, J. A. Hyperferritinemia and inflammation. Int Immunol 29, 401–409 (2017).
Fletcher, C. & Peto, R. The natural history of chronic airflow obstruction. Br Med J 1, 1645–1648, https://doi.org/10.1136/bmj.1.6077.1645 (1977).
Vogelmeier, C. F. et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American journal of respiratory and critical care medicine 195, 557–582, https://doi.org/10.1164/rccm.201701-0218PP (2017).
Seemungal, T. A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 157, 1418–1422, https://doi.org/10.1164/ajrccm.157.5.9709032 (1998).
Donaldson, G. C., Seemungal, T. A., Bhowmik, A. & Wedzicha, J. A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57, 847–852 (2002).
Dransfield, M. T. et al. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 195, 324–330, https://doi.org/10.1164/rccm.201605-1014OC (2017).
Zhang, W. Z., Butler, J. J. & Cloonan, S. M. Smoking-induced iron dysregulation in the lung. Free radical biology & medicine, https://doi.org/10.1016/j.freeradbiomed.2018.07.024 (2018).
Whitby, P. W., Vanwagoner, T. M., Seale, T. W., Morton, D. J. & Stull, T. L. Transcriptional profile of Haemophilus influenzae: effects of iron and heme. J Bacteriol 188, 5640–5645, https://doi.org/10.1128/JB.00417-06 (2006).
Minandri, F. et al. Role of Iron Uptake Systems in Pseudomonas aeruginosa Virulence and Airway Infection. Infect Immun 84, 2324–2335, https://doi.org/10.1128/IAI.00098-16 (2016).
Carraway, M. S., Ghio, A. J., Taylor, J. L. & Piantadosi, C. A. Induction of ferritin and heme oxygenase-1 by endotoxin in the lung. Am J Physiol 275, L583–592, https://doi.org/10.1152/ajplung.1998.275.3.L583 (1998).
Damron, F. H., Oglesby-Sherrouse, A. G., Wilks, A. & Barbier, M. Dual-seq transcriptomics reveals the battle for iron during Pseudomonas aeruginosa acute murine pneumonia. Sci Rep 6, 39172, https://doi.org/10.1038/srep39172 (2016).
Seifert, M. et al. Effects of the Aspergillus fumigatus siderophore systems on the regulation of macrophage immune effector pathways and iron homeostasis. Immunobiology 213, 767–778, https://doi.org/10.1016/j.imbio.2008.07.010 (2008).
Sharma, R. K. & Chakrabarti, S. Anaemia secondary to erythropoietin resistance: important predictor of adverse outcomes in chronic obstructive pulmonary disease. Postgraduate medical journal https://doi.org/10.1136/postgradmedj-2015-133814 (2016).
Terashima, T., Wiggs, B., English, D., Hogg, J. C. & van Eeden, S. F. The effect of cigarette smoking on the bone marrow. American journal of respiratory and critical care medicine 155, 1021–1026, https://doi.org/10.1164/ajrccm.155.3.9116981 (1997).
Rybinska, I. & Cairo, G. Mutual Cross Talk Between Iron Homeostasis and Erythropoiesis. Vitamins and hormones 105, 143–160, https://doi.org/10.1016/bs.vh.2017.01.001 (2017).
McCrea, K. A., Ensor, J. E., Nall, K., Bleecker, E. R. & Hasday, J. D. Altered cytokine regulation in the lungs of cigarette smokers. Am J Respir Crit Care Med 150, 696–703, https://doi.org/10.1164/ajrccm.150.3.8087340 (1994).
Vlahos, R. & Bozinovski, S. Role of alveolar macrophages in chronic obstructive pulmonary disease. Frontiers in immunology 5, 435, https://doi.org/10.3389/fimmu.2014.00435 (2014).
Shaykhiev, R. et al. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. Journal of immunology (Baltimore, Md.: 1950) 183, 2867–2883, https://doi.org/10.4049/jimmunol.0900473 (2009).
Hodge, S. et al. Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. American journal of respiratory cell and molecular biology 37, 748–755, https://doi.org/10.1165/rcmb.2007-0025OC (2007).
Recalcati, S., Locati, M., Gammella, E., Invernizzi, P. & Cairo, G. Iron levels in polarized macrophages: regulation of immunity and autoimmunity. Autoimmunity reviews 11, 883–889, https://doi.org/10.1016/j.autrev.2012.03.003 (2012).
Ryan, T. P. et al. Pulmonary ferritin: differential effects of hyperoxic lung injury on subunit mRNA levels. Free radical biology &. medicine 22, 901–908 (1997).
Worwood, M., Dawkins, S., Wagstaff, M. & Jacobs, A. The purification and properties of ferritin from human serum. Biochem J 157, 97–103 (1976).
Ghosh, S., Hevi, S. & Chuck, S. L. Regulated secretion of glycosylated human ferritin from hepatocytes. Blood 103, 2369–2376, https://doi.org/10.1182/blood-2003-09-3050 (2004).
Stites, S. W., Plautz, M. W., Bailey, K., O’Brien-Ladner, A. R. & Wesselius, L. J. Increased concentrations of iron and isoferritins in the lower respiratory tract of patients with stable cystic fibrosis. American journal of respiratory and critical care medicine 160, 796–801, https://doi.org/10.1164/ajrccm.160.3.9811018 (1999).
Sibille, J. C., Kondo, H. & Aisen, P. Interactions between isolated hepatocytes and Kupffer cells in iron metabolism: a possible role for ferritin as an iron carrier protein. Hepatology 8, 296–301 (1988).
Leimberg, M. J., Prus, E., Konijn, A. M. & Fibach, E. Macrophages function as a ferritin iron source for cultured human erythroid precursors. J Cell Biochem 103, 1211–1218, https://doi.org/10.1002/jcb.21499 (2008).
Ghio, A. J. & Hilborn, E. D. Indices of iron homeostasis correlate with airway obstruction in an NHANES III cohort. International journal of chronic obstructive pulmonary disease 12, 2075–2084, https://doi.org/10.2147/copd.S138457 (2017).
Lee, C. H. et al. Association of serum ferritin levels with smoking and lung function in the Korean adult population: analysis of the fourth and fifth Korean National Health and Nutrition Examination Survey. International journal of chronic obstructive pulmonary disease 11, 3001–3006, https://doi.org/10.2147/copd.s116982 (2016).
Shibata, Y. et al. Elevated serum iron is a potent biomarker for spirometric resistance to cigarette smoke among Japanese males: the Takahata study. PloS one 8, e74020, https://doi.org/10.1371/journal.pone.0074020 (2013).
Woodruff, P. G. et al. Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. N Engl J Med 374, 1811–1821, https://doi.org/10.1056/NEJMoa1505971 (2016).
Galban, C. J. et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 18, 1711–1715, https://doi.org/10.1038/nm.2971 (2012).
O’Neal, W. K. et al. Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study. Journal of translational medicine 12, 9, https://doi.org/10.1186/1479-5876-12-9 (2014).
Freeman, C. M. et al. Design of a multi-center immunophenoty** analysis of peripheral blood, sputum and bronchoalveolar lavage fluid in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). Journal of translational medicine 13, 19, https://doi.org/10.1186/s12967-014-0374-z (2015).
Wells, J. M. et al. Safety and Tolerability of Comprehensive Research Bronchoscopy in COPD: Results from the SPIROMICS Bronchoscopy Sub-Study. Ann Am Thorac Soc, https://doi.org/10.1513/AnnalsATS.201807-441OC (2019).
Acknowledgements
We thank Dr. Augustine M.K. Choi for critical discussion and insight. This work is supported by the US National Institute of Health–National Heart, Lung and Blood Institute R00-HL125899 (S.M.C.), U01 HL128964, U01 HL137880, P01 HL114501, R01 HL122438, R01 HL136682 (F.J.M.), T32-HL134629, a COPD Research Grant from the CHEST foundation in partnership with AstraZeneca LP and Sunovion Pharmaceuticals Inc and the Stony-Wold Herbert Fund (W.Z.Z). The authors thank the SPIROMICS participants and participating physicians, investigators and staff for making this research possible. More information about the study and how to access SPIROMICS data is at www.spiromics.org. We would like to acknowledge the following current and former investigators of the SPIROMICS sites and reading centers: Neil E Alexis, MD; Wayne H Anderson, PhD; Mehrdad Arjomandi, MD; Igor Barjaktarevic, MD, PhD; R Graham Barr, MD, DrPH; Lori A Bateman, MSc; Surya P Bhatt, MD; Eugene R Bleecker, MD; Richard C Boucher, MD; Russell P Bowler, MD, PhD; Stephanie A Christenson, MD; Alejandro P Comellas, MD; Christopher B Cooper, MD, PhD; David J Couper, PhD; Gerard J Criner, MD; Ronald G Crystal, MD; Jeffrey L Curtis, MD; Claire M Doerschuk, MD; Mark T Dransfield, MD; Brad Drummond, MD; Christine M Freeman, PhD; Craig Galban, PhD; MeiLan K Han, MD, MS; Nadia N Hansel, MD, MPH; Annette T Hastie, PhD; Eric A Hoffman, PhD; Yvonne Huang, MD; Robert J Kaner, MD; Richard E Kanner, MD; Eric C Kleerup, MD; Jerry A Krishnan, MD, PhD; Lisa M LaVange, PhD; Stephen C Lazarus, MD; Fernando J Martinez, MD, MS; Deborah A Meyers, PhD; Wendy C Moore, MD; John D Newell Jr, MD; Robert Paine, III, MD; Laura Paulin, MD, MHS; Stephen P Peters, MD, PhD; Cheryl Pirozzi, MD; Nirupama Putcha, MD, MHS; Elizabeth C Oelsner, MD, MPH; Wanda K O’Neal, PhD; Victor E Ortega, MD, PhD; Sanjeev Raman, MBBS, MD; Stephen I. Rennard, MD; Donald P Tashkin, MD; J Michael Wells, MD; Robert A Wise, MD; and Prescott G Woodruff, MD, MPH. The project officers from the Lung Division of the National Heart, Lung, and Blood Institute were Lisa Postow, PhD, and Lisa Viviano, BSN; SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), grants from the NIH/NHLBI (U01 HL137880 and U24 HL141762), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; Novartis Pharmaceuticals Corporation; Nycomed GmbH; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan.
Author information
Authors and Affiliations
Contributions
S.M.C conceived the hypothesis and designed the study. W.Z.Z. and S.M.C. interpreted the data and drafted the initial manuscript. S.A.K., J.J.B., and K.K. performed the measurements in the study. S.O. and R.G.C. provided samples for the validation cohort. W.K.O, C.M.F., S.A.C., S.P.P., J.M.W., C.D., N.P., I.B., P.G.W., C.C., R.P.B., A.P.C., G.J.C., R.P., N.H., M.K.H., R.J.K., J.L.C., F.J.M., were involved in data collection and processing. C.O. and K.V.B. provided the statistical analysis. All authors participated in manuscript editing for critical intellectual content and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
Dr. Bowler served on the advisory boards (GlaxoSmithKline, Boehringer Ingelheim, and Mylan Pharmaceuticals) and received research grants from GlaxoSmithKline and Boehringer Ingelheim not related to this manuscript and these activities have not influenced my work on this manuscript. Dr. Christenson reports personal fees from AstraZeneca, personal fees from GlaxoSmithKline, personal fees from Amgen, personal fees from Glenmark, personal fees from Sunovion, non-financial support from Genentech, non-financial support from Medimmune, outside the submitted work. Dr. Comellas reports grants from NIH, non-financial support from VIDA, personal fees from GSK, outside the submitted work. Dr. Cooper reports grants from Equinox Health Clubs, personal fees from Equinox Health Clubs, grants from Amgen, personal fees from PulmonX, other from GlaxoSmithKline, outside the submitted work; and work part-time on scientific engagement for the GlaxoSmithKline Global Respiratory Franchise. Dr. Criner reports grants from Boehringer- Ingelheim, grants from Novartis, grants from Astra Zeneca, grants from Respironics, grants from MedImmune, grants from Actelion, grants from Forest, grants from Pearl, grants from Ikaria, grants from Aeris, grants from PneumRx, grants from Pulmonx, other from HGE Health Care Solutions, Inc, other from Amirall, other from Boehringer- Ingelheim, other from Holaira, outside the submitted work. Dr. Han reports personal fees from GSK, personal fees from BI, personal fees from AZ, other from Novartis, other from Sunovion, outside the submitted work. Dr. Hansel reports grants and personal fees from AstraZeneca, grants from Boehringer Ingelheim, grants from NIH, grants from COPD Foundation, personal fees from Mylan, outside the submitted work. Dr. Barjaktarevic reports personal fees from Astra Zeneca, personal fees from Boehringer Ingelheim, grants from AMGEN, grants and personal fees from GE Healthcare, personal fees from Grifols, personal fees from Verona Pharma, personal fees from GSK, personal fees from CSL Behring, personal fees from Mylan/Theravance, during the conduct of the study. Dr. Kaner reports personal fees from Boehringer Ingelheim, grants and personal fees from Genentech, outside the submitted work. Dr. Martinez reports personal fees and non-financial support from American College of Chest Physicians, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Boehringer Ingelheim, non-financial support from ProterrixBio, personal fees from Columbia University, personal fees and non-financial support from ConCert, personal fees and non-financial support from Genentech, personal fees and non-financial support from GlaxoSmithKline, personal fees and non-financial support from Inova Fairfax Health System, personal fees from Integritas, personal fees from MD Magazine, personal fees from Methodist Hospital Brooklyn, personal fees and non-financial support from Miller Communicatinos, personal fees and non-financial support from National Association for Continuing Education, personal fees and non-financial support from Novartis, personal fees from New York University, personal fees and non-financial support from Pearl Pharmaceuticals, personal fees and non-financial support from PeerView Communications, personal fees and non-financial support from Prime Communications, personal fees and non-financial support from Puerto Rican Respiratory Society, personal fees and non-financial support from Chiesi, personal fees and non-financial support from Sunovion, personal fees and non-financial support from Theravance, personal fees from UpToDate, personal fees from WebMD/MedScape, personal fees from Western Connecticut Health Network, other from Afferent/Merck, non-financial support from Gilead, non-financial support from Nitto, personal fees from Patara/Respivant, personal fees from PlatformIQ, personal fees and non-financial support from Potomac, other from Biogen, personal fees and non-financial support from University of Alabama Birmingham, other from Veracyte, non-financial support from Zambon, personal fees from American Thoracic Society, grants from NIH, personal fees and non-financial support from Physicians Education Resource, personal fees from Rockpointe, other from Prometic, personal fees from Rare Disease Healthcare Communications, other from Bayer, other from Bridge Biotherapeutics, personal fees and non-financial support from Canadian Respiratory Network, other from ProMedior, personal fees and non-financial support from Teva, personal fees from France Foundation, personal fees and non-financial support from Dartmouth, outside the submitted work. Dr. Woodruff reports personal fees from Glaxosmithkline, personal fees from NGM biopharmaceuticals, personal fees from Amgen, personal fees from Glenmark Pharmaceuticals, personal fees from Theravance, personal fees from Clarus Ventures, personal fees from Astra Zeneca, personal fees from 23andMe, personal fees from Sanofi, personal fees from Regeneron, personal fees from Genentech, outside the submitted work. Dr. Wells reports grants from NIH/NHLBI, during the conduct of the study; grants from NIH/NCATS, grants from Bayer, grants and other from GSK, other from Boehringer Ingelheim, grants and other from Mereo BioPharma, other from Quintiles, other from PRA, outside the submitted work. All other authors have no conflicts to disclose.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zhang, W.Z., Oromendia, C., Kikkers, S.A. et al. Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS. Sci Rep 10, 10562 (2020). https://doi.org/10.1038/s41598-020-67047-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-020-67047-w
- Springer Nature Limited
This article is cited by
-
Recent evidence from omic analysis for redox signalling and mitochondrial oxidative stress in COPD
Journal of Inflammation (2022)
-
Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease
Respiratory Research (2021)